Molbio Diagnostics IPO

Molbio Diagnostics is an innovative point-of-care (POC) diagnostics player focused on expanding access to rapid, accurate and cost-effective diagnostic solutions for infectious and non-communicable diseases. It has developed the ‘Truenat’ platform, a battery-operated, portable PCR-based molecular diagnostic platform designed for decentralised testing in resource-limited settings. As of March 31, 2025, Truenat was patented in over 100 countries and supported testing for 30 diseases through 42 assays, including TB, COVID, Hepatitis B and C, HIV and HPV. The company operates in a high-entry-barrier market, with its platform undergoing 13 years of R&D and receiving ICMR certification. Its TB test chip is among the only rapid molecular tests globally endorsed by WHO for initial TB diagnosis and rifampicin resistance detection. Through its subsidiaries and partners, the company also offers radiology, digital pathology and breast health screening solutions, while developing additional products and platforms to address the growing global POC diagnostics market.